Tomorrow's rep, tomorrow's market - Pharmaceutical Representative
Saturday, Nov 21, 2009
Search

Tomorrow's rep, tomorrow's market
Tomorrow's rep, tomorrow's market

Pharmaceutical Representative


But what differentiates them from their peers is not what they know, it's what they do with what they know. I would encourage each company to think more about getting people to translate knowledge in their head into the actions they can take.

HERMAN: How?

SNOW: The field sales force has to be more focused on solutions and on patient outcomes. That means that, from a brand standpoint, reps have to be able to convey solutions for the practice and for the patient long term.

JENNINGS: Before we can prepare our reps, we have to define what the profile of that rep should be and the actual role they're playing in the practice. I see a lot of pharma companies using the tiered approach by having a sales representative, a customer-service rep, a medical-science liaison, a clinical-nurse educator, on-call nurses, and others approach the practice. And as we start to look at doctors' offices more around therapeutic area, we can plug and play those different roles so we can offer the doctor a full understanding of the disease state, therapeutic class and the offerings to treat their patient population.

TRAINING DAY(S)

BREITSTEIN: Do pharma companies have the necessary training systems in place to ensure that reps have the skills they need?

LAMBERT: From a pure training perspective, Big Pharma does a pretty darn good job of investing in their people. Having been in specialty, I've looked at hiring Big Pharma people simply because of the rigor and discipline that they've had in their training.

ROSENTHAL: But training is a temporary state of affairs. District managers are only with an individual rep one out of 40 or 50 days — if they're lucky.

JENNINGS: It's important to understand how these managers are going to coach the reps. We have a population of first-line managers that don't have the experience around the scientific approach. Even when it comes to business acumen, depending on the pharmaceutical company you've worked for, you might have been exposed to only a very narrow scope of what a district manager might do. We need to make sure the district managers know how to be successful, because they are the number one reason reps leave the job.

SNOW: You also have to consider that the variability of reps across the United States can be quite large. Distance-learning platforms can help the industry in diagnosing individual rep needs, which is different than a one-size-fits-all three-day event.

KEEFER: We're also seeing the benefit of new gaming technology that puts very high science into a training format that reps can identify with. That's really starting to mushroom in terms of interest in the industry.

GO-GO-GADGET REPS

HERMAN: Within the sales organization, where are companies finding the most success with new technology?

STICKLER: We have only 51 representatives across the country, divided into two different sales forces and two different therapeutic areas. We've made a decision to go with the tablet PCs and electronic promotional material.

One of the quick learnings is that sit-down meetings are by far the most attractive venue to use tablet PCs and promotional material. There's a lot of intrigue by the healthcare professionals, and they're giving us a lot more time. In other situations, that doesn't work as well — like when reps have hallway conversations and other quick, impromptu meetings.

SNOW: We've broadly deployed tablets in specialty and in primary care and have been working with the technology for over a year.

Traditionally, sales reps used printed promotional material about 25 to 30% of the time. With interactive technology, that can be substantially higher. But what we've seen is about garbage in/garbage out — if the interactive materials are good, then you can have impressive results.


ADVERTISEMENT

Survey
The more people talk about healthcare reform the less consensus there is, what do you think of current efforts to reform the system?
Healthcare reform is
Good for pharma
Bad for pharma
Doomed to failure
An idea whose time has come
Good for pharma
18%
Bad for pharma
37%
Doomed to failure
24%
An idea whose time has come
21%
GOOGLE ADVERTISEMENTS
Source: Pharmaceutical Representative,
Click here